GLP-1 lifestyle program · for employers and health plans

The lifestyle layer that makes GLP-1 therapy work

Better adherence, preserved muscle and a supported off-ramp, with clinician sign-off on every plan change and outcomes reported back to the payer.

Clinician sign-offMuscle preservationStructured off-rampWorks with or without a wearable
The challenge

Payers are spending heavily on GLP-1s and not keeping the results

1 in 12

members remain on GLP-1 treatment after three years

77%

of large US employers rate managing GLP-1 costs as extremely or very important

Regain

after stopping, plus lean-muscle loss during treatment, with little structured support

Sources: Prime Therapeutics data, cited by Mercer, “GLP-1 considerations for 2026”; Mercer employer survey.

Why now

As drug prices fall, value moves to the program around the drug

Prices are falling

US agreements cut GLP-1 prices from over $1,000 to as low as $245 a month for eligible patients, and oral options are arriving.

Payers want lifestyle support

Employers and plans increasingly tie coverage to lifestyle and behavioral programs.

Medicare is paying for outcomes

The CMS ACCESS Model pays for technology-enabled care tied to outcomes in chronic conditions.

Sources: IQVIA, “Outlook for Obesity in 2026”; MedCity News, Jan 2026; AAMC on the CMS ACCESS Model.

The program

One program across the whole GLP-1 journey

1
START

Baseline and onboarding

Body composition, activity, nutrition and gut-health baseline, plus a side-effect plan.

2
MAINTAIN

Adherence and muscle

Protein and strength targets, GI side-effect support and early flags for drop-off.

3
OFF-RAMP

Supported step-down

A structured taper with the prescriber, and habits that hold the results.

A licensed clinician reviews and signs off every plan change. Activity comes from a wearable, the phone or a weekly check-in; nutrition and gut health come from LIWEL’s own nutrition engine.

Prescribing stays with the member’s own clinician.
Outcomes

The payer sees what its GLP-1 spend is buying

Reported per cohort to the employer or plan, de-identified, every quarter.

OutcomeWhat we measureWhy the payer cares
AdherenceMonths on therapy; drop-off flags acted onValue from each fill
Muscle preservationLean-mass trend, strength and activityHealthier weight loss
Side effectsGI symptoms logged and resolvedFewer early stops
Off-rampWeight held after step-downLower long-term drug cost

Outcome definitions and targets are agreed with each buyer. LIWEL has no US results yet; the first pilot is planned for 2027.

What sets LIWEL apart

We measure what keeps the results

Measured muscle preservation

Lean mass and strength tracked, not just the scale.

Gut and side-effect support

Gut-health data and nutrition guidance to keep members on therapy.

A structured off-ramp

Step-down with the prescriber, monitored afterwards.

Clinician sign-off, one record

With or without a wearable: one record, every change approved.

How we work with payers

Paid per member, with part of the fee tied to outcomes

FIRST

Self-insured employers

A per-member-per-month fee, with a share at risk on adherence and outcomes.

NEXT

Health plans, PBMs and obesity practices

The program as a condition of coverage, or white-labelled for prescribers.

LATER

Medicare and cash-pay members

Outcome-based Medicare models, and direct subscriptions.

Evidence

Two tracks to evidence in 2027

US · GLP-1 PILOT

Employer pilot

About 100–200 members on GLP-1s for six months with a launch employer. Readouts: adherence at 3 and 6 months, lean-mass trend, side-effect resolution and member experience, reported by data tier.

US · IRB RESEARCH STUDY

Randomized study

Standard care vs LIWEL, with lean mass measured by DEXA, testing early-signal hypotheses. Starts after the MVP.

Gate before launch

The clinical team signs off the no-device pathway: a weekly check-in of about two minutes and a validated home strength test.

Pilot and study size, partners, states and dates are planning assumptions, to be confirmed.

Team and partners

Clinical, technical and healthcare leadership

N

Neela

Founder & CEO

Serial founder with 20+ years of GCC leadership at Cisco, Juniper and Epicor.

PS

Pankaja Shankar

Co-founder & CTO

Leads the core AI and predictive engine.

CR

Dr. Chithra Ram

Co-founder · Clinical

Neuroradiologist; fellowship in neuroradiology at Duke.

GC

Giri Chenji

Clinical & Regulatory

Former CTO, Immuneel; Deloitte Health (US).

Gut-health data

Orcasho, licensed data partner by API (terms to be signed). Nutrition engine built in-house.

Platform development

Nisarga En-Tech, India, under development and licence agreements.

Finance & legal

US fractional CFO · Sathish Srinivasan, Legal Counsel

We’re hiring

GTM lead, Platform Architect, and a US obesity-medicine physician advisor.

Work with us

Let’s design a pilot together

We’re looking to talk with organizations that want their GLP-1 spend to deliver results that last.

  • Self-insured employers and benefits consultants
  • Obesity-medicine physicians
  • Health plans and PBMs
  • Investors backing the US pilot